Ad
related to: vvus stock price images of women free fullhugealerts.com has been visited by 10K+ users in the past month
Search results
Results from the WOW.Com Content Network
VIVUS' (NAS: VVUS) stock was down 25% for November, though still up 15% for the year. Its drug Qsymia is the first obesity drug to be approved and reach the market in more than a decade, but its ...
For premium support please call: 800-290-4726 more ways to reach us
We are initiating coverage of VIVUS, Inc. (VVUS) with a $10.00 price target based on our revenue forecasts for approved products. In addition to a portfolio of weight loss, exocrine pancreatic ...
VIVUS has traded in a 52-week trading range of $9.86 to $31.21, and the consensus analyst price target from Thomson Reuters was $19.59 before the effects of today's earnings.
Vivus (VVUS) shares are trading around 15% higher Tuesday after U.S. Food and Drug Administration reviewers said its weight-loss drug Qnexa indeed helps reduce weight. Shares of rivals Orexigen ...
For premium support please call: 800-290-4726 more ways to reach us
You are free: to share – to copy, distribute and transmit the work; to remix – to adapt the work; Under the following conditions: attribution – You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses ...
For premium support please call: 800-290-4726 more ways to reach us
Ad
related to: vvus stock price images of women free fullhugealerts.com has been visited by 10K+ users in the past month